Congressional Testimony

2002

December

• Janet Woodcock, M.D. - December 11, 2002
  Director, Center for Drug Evaluation and Research, Food and Drug Administration before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, U.S. House of Representatives.
• Karen Midthun, M.D. - December 10, 2002
  Director, Office of Vaccine Research and Review, Center for Biologics Evaluation and Research Food and Drug Administration Department of Health and Human Services before the Committee on Government Reform U.S. House of Representatives.

November

• David W. Feigal, M.D., M.P.H. - November 14, 2002
  Director, Center for Devices and Radiological Health Food and Drug Administration, Department of Health and Human Services before the Committee on Government Reform U.S. House of Representatives.

October

• Lester M. Crawford, D.V.M., Ph.D. - October 9, 2002
  Deputy Commissioner, Food and Drug Administration, before the Subcomittee on Health, Committee on Energy and Commerce, House of Representatives.
• Lester M. Crawford, D.V.M., Ph.D. - October 8, 2002, Deputy Commissioner, Food and Drug Administration, before the Senate Subcommittee on Oversight of Government Management, Restructuring and the District of Columbia on the Regulatory Framework Under the Dietary Supplement Health and Education Act.
• Jesse L.Goodman, M.D., M.P.H. - October 3, 2002
  Director, Deputy Director of the Center for Biologics Evaluation and Research before the Subcommittee on Criminal Justice, Drug Policy and Human ResourcesCommittee on Government on FDA's Response to the Emerging Threat of West Nile Virus Reform United States House of Representatives.

September

• Jesse Goodman, M.D., MPH, - September 24, 2002
  Director, Deputy Director of the Center for Biologics Evaluation and Research, to discuss FDA's response to the emerging threat of transmission of West Nile virus (WNV) through blood and tissue.

August

• Gary Dykstra - August 5, 2002
  Director, Southeast Regional Office, Office of Regulatory Affairs, FDA's efforts to help ensure that FDA-regulated products coming through the port of Tampa are safe and not used as potential vehicles for terrorist acts while minimizing the impact on the free flow of trade.

July

• Joseph A. Levitt - July 31, 2002
  Director, Center for Food Safety and Applied Nutrition, Food and Drug Administration, Subcommittee on Oversight of Government Management, Restructuring and the Dictrict of Columbia United States Senate dietary supplements and their use for weight-loss purposes.
• William K. Hubbard- July 25, 2002
  Senior Associate Commissioner, Policy, Planning and Legislation, Food and Drug Administration, Subcommittee on Health, Committee on Energy and Commerce, U.S. House of Representatives to discuss concerns related to the importation of drugs into the United States.
• William K. Hubbard- July 9, 2002
  Senior Associate Commissioner, Policy, Planning and Legislation, Food and Drug Administration, Special Committee on Aging, United States Senate to discuss concerns related to the importation of drugs into the United States.

June

• Lester M. Crawford, D.V.M., Ph.D. - June 12, 2002
  Deputy Commissioner, Food and Drug Administration, Committee on Governmental Affairs United States Senate to discuss the shortages of childhood vaccines.

April

• Lester M. Crawford, D.V.M., Ph.D. - April 30, 2002
  Deputy Commissioner, Food and Drug Administration, Subcommittee on Oversight of Government Management, Restructuring and the District of Columbia discuss the safety of Federal school lunches.

March

• Lester M. Crawford, D.V.M., Ph.D. - March 21, 2002
  Deputy Commissioner, Food and Drug Administration, United States House of Representatives Committee on Appropriations to discuss FY 2003 budget.
• Lester M. Crawford, D.V.M., Ph.D. - March 6, 2002
  Deputy Commissioner, Food and Drug Administration, Subcommittee on Health Committee on Energy and Commerce Agency's success in implementing the Prescription Drug User Fee Act and to emphasize the importance of reauthorizing this law in advance of its September 30, 2002, expiration date.

February

• Written Statement for the Record regarding Mammography Quality Standards Act (MQSA) of 1992. February 28, 2002
  Subcommitte on Public Health Committee on Health, Education, Labor, and Pensions -- Subcommittee on Labor, Health and Human Services and Education Committee on Appropriations.
• John K. Jenkins, M.D., February 12, 2002
  Director, Office of New Drugs, CDER, Food and Drug Administration, Committee on Health, Education, Labor, and Pensions to talk about the drug OxyContin.